Shares of Moderna (NASDAQ: MRNA) were falling 3.3% as of 3:34 p.m. EDT on Friday. The decline came after The Wall Street Journal reported that the U.S. Food and Drug Administration is delaying a decision on Emergency Use Authorization for Moderna's COVID-19 vaccine in adolescents ages 12 through 17.
The FDA's delay is related to potential concerns that Moderna's vaccine could increase the risks of heart inflammation in rare cases among younger individuals. Several Nordic countries have halted the use of the vaccine in young age groups, especially young men, due to this issue.
Image source: Getty Images.
Source Fool.com